Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01310686
Active, not recruiting
: March 8, 2011
Last Update Posted
: November 13, 2017
West Coast Retina Medical Group, Inc.
Information provided by (Responsible Party):
Arthur D. Fu, MD, West Coast Retina Medical Group, Inc.
Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment [ Time Frame: This is a one time only blood draw. ]
Secondary Outcome Measures
To evaluate demographic and clinical characteristics in patients treated with anti-VEGF therapy who fail to respond completely. [ Time Frame: This is a one time only blood draw and assessment of clinical characteristics. ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients diagnosed with Wet Age-Related Macular Degeneration
Ability to provide written informed consent for participation in this study
Subjects diagnoses of neovascular AMD who are on a monthly anti-VEGF regimen (have had >10 or more ranibizumab and/or bevacizumab injections within the last year) and who still have intra-retinal or subretinal fluid as confirmed by the Investigator
Subjects with a Pigment Epithelial Detachment Exclusively
Subjects with Serous Pigment Epithelial Detachments